Hepatitis B Virus

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Stephen A. Harrison, MD, medical director of Pinnacle Clinical Research in San Antonio, provides an overview of the topics discussed at the meeting ranging from nonalcoholic steatohepatitis to hepatitis B to liver cancer.

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Robert S. Brown, MD, from the Weill Cornell Medical Center, examines “who to treat” among patients with hepatitis B based on a panel discussion from the meeting.

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Robert Gish, MD, an adjunct professor at the University of Nevada Reno School of Medicine, provides an overview of a presentation on hepatitis B that focused on which patients benefit the most from treatment.

SAN ANTONIO — The National Liver Congress will convene October 25th, providing a broad scientific program and exhibit of products and services important for all practitioners involved in the care of patients with liver disease.

Recent study data showed disparities in hepatitis B virus infection rates between ethnic groups as well as among between U.S.-born and foreign-born patients.

WASHINGTON — A trivalent hepatitis B virus vaccine demonstrated noninferiority in adults older than age 18 years and superiority in adults aged 45 years or older compared with a monovalent vaccine, according to phase 3 study data presented at IDWeek.

With several highly effective, curative direct-acting antiviral options for patients with hepatitis C, the focus has changed from management of the viral infection to a march toward global elimination.

Statin therapy correlated with a reduced risk for hepatocellular carcinoma in patients with chronic hepatitis B, according to results published in Hepatology.

Among the most frequently read stories in infectious disease last week was Merck’s announcement that its Ebola vaccine was being considered for FDA approval.

Results from an estimation model revealed that Australia will marginally miss both its local targets and the WHO’s global targets for eliminating chronic hepatitis B.